insights_auto
Outlook: 33.3% bullish·4.8% bearish
Go to analysischevron_right
ILMN:NASDAQ
Illumina Inc
$262.66
arrow_upward
+0.05%(+0.12) 1D
$262.96
arrow_upward
+0.11% (+0.30)bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ILMN...
Open
$268.93
High
$270.94
Low
$260.24
Mkt. cap
39.66B
Avg. vol.
3.71M
Volume
1.90M
P/E ratio
48.82
52-wk high
$309.34
52-wk low
$94.00
EPS
$5.38
Beta
1.41
Shares outstanding
151.00M
No. of employees
9K
Open
$268.93
High
$270.94
Low
$260.24
Mkt. cap
39.66B
Avg. vol.
3.71M
Volume
1.90M
P/E ratio
48.82
52-wk high
$309.34
52-wk low
$94.00
EPS
$5.38
Beta
1.41
Shares outstanding
151.00M
No. of employees
9K
News stories
From web sources and news partners
ad-hoc-news.de
·
2 days ago
BofA raises Illumina stock target to USD 168.00
Yahoo Finance
·
3 days ago
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Seeking Alpha
·
1 month ago
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added (BE:NYSE)
Profile
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Wikipedia
About Illumina Inc
CEOJacob Thaysen
Employees8.62K
Founded1998
HeadquartersSan Diego, California, United States
SectorHealth care
Websiteillumina.com
Analyst ratings
Based on 15 analysts giving stock ratings to ILMN in the past 3 months
Buy
Buy
9
Hold
3
Sell
3
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for ILMN in the last 3 months.
Highest
Current $262.66
$320.00 (+21.83%)
Average
$247.40 (-5.81%)
Lowest
$113.00 (-56.98%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $300.00 | +14.2% | 10/19/2026 |
Eve Burstein Bernstein | Hold | Reiterated | $215.00 | -18.1% | 10/19/2026 |
Casey Woodring J.P. Morgan | Buy | Maintained | $320.00 | +21.8% | 10/16/2026 |
Daniel Brennan TD Cowen | Hold | Maintained | $270.00 | +2.8% | 10/13/2026 |
Lu Li Bank of America Securities | Sell | Maintained | $168.00 | -36% | 10/09/2026 |
Michael Ryskin Bank of America Securities | Sell | Maintained | $168.00 | -36% | 10/09/2026 |
Luke Sergott Barclays | Sell | Maintained | $200.00 | -23.9% | 10/07/2026 |
Dan Leonard RBC Capital | Buy | Maintained | $310.00 | +18% | 10/04/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $305.00 | +16.1% | 10/01/2026 |
Puneet Souda Leerink Partners | Buy | Maintained | $300.00 | +14.2% | 09/29/2026 |
David Westenberg Piper Sandler | Buy | Reiterated | $305.00 | +16.1% | 09/28/2026 |
Daniel Arias Stifel Nicolaus | Buy | Maintained | $225.00 | -14.3% | 09/15/2026 |
Unknown Analyst UBS | Buy | Upgraded | $260.00 | -1% | 09/09/2026 |
Doug Schenkel UBS | Buy | Upgraded | $260.00 | -1% | 09/09/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | $235.00 | -10.5% | 09/02/2026 |
Ilya Zubkov Freedom Capital Markets | Hold | Downgraded | $185.00 | -29.6% | 08/05/2026 |
Patrick B Donnelly Citi | Sell | Maintained | $113.00 | -57% | 08/03/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $200.00 | -23.9% | 07/06/2026 |
Tycho Peterson Jefferies | Hold | Maintained | $150.00 | -42.9% | 07/01/2026 |
Unknown Analyst RBC Capital | Buy | Initiated | $170.00 | -35.3% | 05/14/2026 |
Narumi Nakagiri Daiwa | Buy | Upgraded | $155.00 | -41% | 05/14/2026 |
Catherine Ramsey Schulte Robert W. Baird | Hold | Maintained | $137.00 | -47.8% | 02/06/2026 |
Next call in 10 days
Thu, Oct 29, 10:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $1.36
Revenue / Est. (USD)
- / 1.15B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.08B | 1.16B | 1.09B | 1.16B |
Cost of goods sold | 335.00M | 382.00M | 353.00M | 371.00M |
Cost of revenue | 335.00M | 382.00M | 353.00M | 371.00M |
Research and development expenses | 228.00M | 152.00M | 240.00M | 252.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 273.00M | 381.00M | 281.00M | 273.00M |
Operating expense | 517.00M | 549.00M | 538.00M | 543.00M |
Total operating expenses | 852.00M | 931.00M | 891.00M | 914.00M |
Operating income | 232.00M | 228.00M | 200.00M | 245.00M |
Other non operating income | - | 9.00M | 10.00M | 2.00M |
EBT including unusual items | 220.00M | 377.00M | 157.00M | 260.00M |
EBT excluding unusual items | 216.00M | 221.00M | 197.00M | 231.00M |
Income tax expense | 70.00M | 43.00M | 23.00M | 53.00M |
Effective tax rate | 31.82% | 11.41% | 14.65% | 20.38% |
Other operating expenses | - | - | - | - |
Net income | 150.00M | 334.00M | 134.00M | 207.00M |
Net profit margin | 13.84% | 28.82% | 12.28% | 17.86% |
Earnings per share | 1.34 | 1.35 | 1.15 | 1.31 |
Interest and investment income | 9.00M | 10.00M | 11.00M | 8.00M |
Interest expense | -25.00M | -26.00M | -24.00M | -24.00M |
Net interest expenses | -16.00M | -16.00M | -13.00M | -16.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 299.00M | 294.00M | 269.00M | 315.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1